Synthetic drug nicknamed Oz is set to become the major weapon in the fight against multi-drug resistant malaria

What has been described as the biggest breakthrough in malaria treatment of our generation has been developed by an international team including researchers from Monash University.

The new synthetic drug nicknamed Oz is set to become the major weapon in the fight against multi-drug resistant malaria and could be available to patients within three years.

Professor Bill Charman from the Victorian College of Pharmacy said the drug (OZ277/Rbx11160) is cheap and easy to manufacture and has the potential to save millions of lives worldwide.

Professor Charman said it is estimated that malaria kills between one and two million people every year and in sub-Saharan Africa one child dies every 30 seconds from the mosquito born disease.

"We are thrilled with the progress and speed which this drug has been developed and it is now entering human trials in the Europe," he said

"Assuming all goes well we are anticipating Oz will be available to patients in the next three years."

A major goal of the research team was to ensure the compound would be affordable for even the poorest of nations.

At a cost of US $1 per day, Professor Charman said the three day treatment program ensures this will be the case.

He said the ability of the Oz drug to treat drug resistant malaria holds the key to its success where other malaria medicines developed over the years have been less effective.

Professor Charman said the development of the drug has been an international effort with researchers from Monash University, the University of Nebraska Medical Center, the Swiss Tropical Institute and Hoffmann-La Roche of Switzerland working on the project since the late 1990's.

http://www.monash.edu.au

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Experimental malaria vaccine shows promise in protecting pregnant women